Stock Movers cover image

Corcept Therapeutic Soars, Abbott Labs Sinks, Arista Networks Jumps on AI Spending

Stock Movers

00:00

Corcept's Trial Boosts Shares

Carmen Reinke explains Corcept's Phase 3 trial success and 35% survival improvement, and FDA review timing.

Play episode from 00:25
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app